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Abstract This paper describes an LC-MS/MSmethod to deter-
mine the concentration of spironolactone and its metabolites 7-
alpha-methylthiospironolactone and canrenone in blood plasma
samples. The resulting assay is simple (using protein precipita-
tion for sample preparation) and sensitive (the lower limit of
quantification is close to 0.5 ng/ml) while requiring only 50 μl
of plasma, making it especially suitable for analyzing samples
obtained from pediatric and neonatal patients where sample sizes
are limited. The sensitivity is achieved by using ammonium fluo-
ride as an eluent additive, which in our case amplifies the signal
from our analytes in the plasma solution on average about 70
times. The method is fully validated according to the European
Medicines Agency’s guideline and used for the measurement of
pediatric patients’ samples in clinical trials for evaluating oral
spironolactone’s and its metabolites’ pharmacokinetics in chil-
dren up to 2 years of age.
Keywords Spironolactone . Ammonium fluoride . Signal
enhancement . Liquid chromatography-mass spectrometry .
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Introduction
Spironolactone (Fig. 1) is a synthetic steroidal antiminera-
locorticoid agent with a structure resembling that of the natu-
ral adrenocorticoid hormone, aldosterone. Spironolactone
competes with aldosterone on aldosterone-sensitive Na+/K+
channels in the distal tubule of the nephron, thereby increasing
the secretion of water and sodium while decreasing the excre-
tion of potassium [1]. It is rapidly and extensively metabolized
in the liver to at least 17 metabolites, with canrenone, 7-alpha-
methylthiospironolactone (two pharmacologically active
spironolactone metabolites, Fig. 1), and 6-beta-hydroxy- 7-
alpha-methylthiospironolactone as the main ones [2].
Spironolactone has been widely used for decades and its side
effects have been studied and documented [3–8], but despite
being used also in children, the dosing recommendations are
based on clinical trials performed in the adult population and/
or expert opinion and clinical experience. As such, studies
evaluating the pharmacokinetic profile of spironolactone in
pediatric age groups contribute to the refinement of
evidence-based dosing recommendations in children.
Analytical methods measuring spironolactone and its me-
tabolites in serum or plasma published in previous studies
have commonly employed separation by reversed phase liquid
chromatography (RPLC), followed by detection either by UV/
VIS spectrophotometry or mass spectrometry. The latter is a
more popular choice, for obvious reasons: lower detection
limits can be achieved and the interference from the complex
sample matrix is decreased. This is especially true for tandem
mass spectrometric detection where the fragmentation of
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molecules creates a characteristic fingerprint and thereby
greatly increases selectivity. Employing these methods has
resulted in quantitation limits for human plasma samples as
low as 2 ng/ml [9]. However, these methods often require
either complex or time-consuming sample preparation steps
such as solid phase extraction, or rather large sample sizes,
ranging from 100 to 1000 μl [9–13]. Since the age and con-
dition of the target population implied much smaller available
plasma volumes, an effort was made to increase the sensitivity
of the assay while keeping it as simple as possible.
One particularly interesting way to increase the assay’s
sensitivity is through eluent additives which due to various
known or unknown mechanisms improve an analyte’s ioniza-
tion and increase the analytical signal. In our case—steroid-
like molecules—an additive that has emerged from the litera-
ture which significantly enhances their ionization is ammoni-
um fluoride [14–16]. The suitability of NH4F as an eluent
additive in LC-MS methods has been thoroughly evaluated
[14–20] and it has been found that the signal-enhancing effect
is dependent on the analyte’s chemical structure, with signal
enhancement and signal suppression both being possible [20].
The mechanism behind the sensitivity improvement in the
negative ionization mode probably stems from the fluoride
ions’ strong basicity in the gas phase, allowing it to capture
protons from the neutral analytes, resulting in HF [14] and the
forming of both [M+F]− ions and [M+FHF]− clusters. Signal
enhancement due to ammonium fluoride in the positive ESI
mode has been demonstrated for some organic acids by aque-
ous normal phase chromatography but the mechanism re-
mains largely unknown [19].
The aim of the present study was to develop and validate the
selective and sensitive HPLC-ESI-MS/MSmethod for the deter-
mination of spironolactone, 7-alpha-methylthiospironolactone,
and canrenone from small volume blood plasma samples and
to evaluate the suitability of NH4F as an eluent additive for the
analytes.
Materials and methods
The clinical study protocol was approved by the Research
Ethics Committee of the University of Tartu (249/M-12,
15.05.2015). For the method development and validation, no
clinical study samples were analyzed. Blood plasma with
EDTA and Citrate Phosphate Dextrose Solution (CPD) for
method development and validation was purchased from the
Blood Centre of Tartu University Hospital.
Chemicals
Spironolactone and canrenone were purchased from Sigma
Aldrich (St. Louis, MO, USA), 7-alpha-methylthiospironolactone
from PharmaSynth (Tartu, Estonia), and spironolactone-D3 (used
as an internal standard, IS) from TLC Pharmaceutical Standards
(Aurora, Ontario, Canada). LC-MS-grade methanol, tetrahydro-
furan (THF), NH4F, and 1,1,1,3,3,3-hexafluoro-2-propanol
(HFIP) were obtained from Sigma Aldrich (St. Louis, MO,
USA). Water was purified (18.2 MΩ·cm at 25 °C and a TOC
value in the range 2–5 ppb) in house using a Millipore
Advantage A10 system from Millipore (Bedford, USA).
Sample preparation
Plasma samples, calibrators, and quality control samples were
stored at −70 °C. For analysis, the samples were thawed at
room temperature. Once at room temperature, the samples
were mixed on an Eppendorf MixMate and 50 μl of plasma
was transferred into a 2-ml polypropylene Eppendorf tube.
One hundred thirty microliters of methanol and 50 μl of IS
(spironolactone-D3) solution in methanol were added. The
samples were then shaken for 2 min at 2050 rpm and subse-
quently centrifuged for 5 min at 27,500×g and 4 °C.
Chromatographic conditions
The Agilent 1290 Infinity (Santa Clara, USA) HPLC system
with a binary pump, a thermostated column compartment, and
an autosampler (thermostated at 4 °C) was used. For the chro-
matographic separation, the YMC-Triart C18 analytical column
(150 × 3.0 mm, 3 μm) was used. To protect the column, an in-
line filter and the YMC-Triart C18 guard column (10 × 3.0 mm,
3 μm) were installed in front of the analytical column. During
analysis, the column was thermostated at 40 °C.
The aqueous phase of the eluent comprised 5 mM HFIP
and 2.5 mM NH4F in a mixture of THF and water (36:1000).
For analysis, isocratic elution withmethanol (35:65) was used.
At the end of every run, the column was flushed with pure
methanol.
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Mass spectrometry
The Agilent 6495 Triple Quadrupole (Santa Clara, USA)
served as a mass analyzer. The heated ESI ionization source
(Agilent JetStream Technology) in the positive mode was
used. Nitrogen served as a nebulizing, sheath, drying, and
collision gas. Sheath gas temperature was set to 350 °C and
drying gas temperature to 250 °C. The data were collected in
the MRM mode; the transitions monitored and the respective
collision energies are listed in Table 1. The LC-MS system
was controlled with the AgilentMassHunterWorkstation soft-
ware version B.07.00. For peak integration and quantitative
calculations, the Agilent MassHunter Quantitative Analysis
software version B.07.00 was used.
Calibration
Matrix-matched calibration was used. Stock solutions at about
1 mg/ml were prepared in methanol and stored at −70 °C. For
spiking, stock solutions were diluted in water. A total of eight
calibration points were prepared in the blood plasma with
concentrations of approximately 0.5, 1, 2, 6, 20, 50, 150,
and 250 ng/ml. Quality control samples were prepared from
different stock solutions at four levels (approximately 0.6 ng/
ml (lower limit of quantification, LLOQ), 4 ng/ml (low),
80 ng/ml (medium), and 220 ng/ml (high) plasma concentra-
tion). Linear regression with 1/x2 weights was used for creat-
ing calibration curves.
Method validation
The method was fully validated according to the European
Medicines Agency’s (EMA) guideline [21]. Linearity was
evaluated by comparing the experimental and measured con-
centrations of the calibration solutions on different days dur-
ing the validation. Inter- and intra-day accuracy and precision
were determined by running a batch of the calibration curve
and quality controls on three different days; selectivity was
evaluated by injecting blank plasma samples from six healthy
volunteers; carry-over was calculated from blank plasma sam-
ples immediately following the highest calibration injection.
Matrix effects were evaluated as described byMatuszewski et al.
[22] by comparing the post-extraction spiked plasma samples
(from six plasma lots obtained from individual donors [21])
and standard solutions in neat solvent at high and low concen-
tration levels. Stability was determined in short-term, freeze, and
thaw cycles, on-instrument, and long-term forms. For short-term
stability evaluation, the spiked samples were kept for 24 h at 20
± 2 °C; for on-instrument stability in the autosampler, the pre-
pared samples were kept at 4 °C for 25 h; a total of three freeze
and thaw cycles were applied for freeze and thaw stability, and
for long-term stability, the spiked plasmas were stored for
5 months at −70 °C.
Results
Limit of quantification, linearity, carry-over, accuracy,
and precision
The final method is a fairly standard LC-MS/MS method with
an aqueous/methanol mobile phase and a well-established
protein precipitation-based sample preparation. LLOQ were
0.53 ng/ml for spironolactone, 0.52 ng/ml for 7-alpha-
methylthiospironolactone, and 0.55 ng/ml for canrenone, low-
er than reported in the literature before [9].
The calibration set comprised eight calibration points (pre-
pared in duplicates), blank and double blank (blank plasma
without IS). The back-calculated concentrations from the
curve remainedwithin ±15% of accuracy. Linearity, expressed
as the coefficient of determination (R2), was >0.93 for all
analytes. Carry-over did not present a problem as all analytes
were undetectable from blank injections after the highest cal-
ibrator, and with regard to selectivity, no interfering peaks for
analytes and the internal standard were found in the double
blank samples. The data for accuracy and precision are pre-
sented in Tables 2 and 3, respectively.
Stability
Stability data for freeze and thaw cycles, short-term, on-instru-
ment, and long-term storage are presented in Table 4. To
Table 1 MRM transitions used
for analysis with collision
energies (CE)
Compound Precursor ion Product ion
Quantifier Qualifier
m/z m/z CE, V m/z CE, V
Spironolactone 341 107 38 341 2
Canrenone 341 107 38 341 2
7-Alpha-methylthiospironolactone 389 341 14 323 14
Spironolactone-D3 344 107 32 341 2
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summarize the results, while the analytes are not strongly affect-
ed by freeze and thaw cycles and both long-term and on-
instrument stability are satisfactory, the plasma stability at room
temperature is rather poor. The corresponding increase in
canrenone content suggests that some of the spironolactone and
7-alpha-methylthiospironolactone might transform into
canrenone. Degradation of spironolactone in rat plasma has been
noted before by Tokumura et al. [23], and the dependence on
temperature and pH as well. This emphasizes the necessity of
careful planning of sample collection in the hospital setting. The
decrease of spironolactone content at room temperature indicates
the need for controlled sampling conditions and quick sample
processing methods to minimize the time samples spend in am-
bient conditions.
Matrix effects
Matrix effects were evaluated for high and low analyte con-
centrations calculating the matrix factors (MF) in six lots of
blank plasmas from individual donors. The results are present-
ed in Table 5. While the IS-normalized MF for spironolactone
lie in a very reasonable range of 97.3–102.3%, the signal of
the other two analytes appears to be amplified in the plasma.
The analysis of peak areas revealed that while the intensities
of 7-alpha-methylthiospironolactone and canrenone remain
about the same in both pure solutions and post-extraction
samples (the matrix effect around 100%), the signals from
spironolactone and its deuterated analogue are somewhat sup-
pressed (ranging 57.0–67.4 and 56.9–68.8%, respectively).
Since the same internal standard is used for all analytes, the
reduction in the IS’s signal is responsible for the apparent in-
crease in 7-alpha-methylthiospironolactone’s and canrenone’s in-
tensities. The matrix-matched calibration in plasma was used to
take the matrix effect into account for all analytes.
Discussion
When using concentrated solutions, interference from IS to
spironolactone’s transitions and vice versa was significant.
Fortunately, because the samples turned out to be sufficiently
dilute, the effect was not significant in our case. Only the
highest calibration points (∼250 ng/ml) were noticeably af-
fected, but since 1/x2 weighted regressions were used, it did
not have a detrimental effect on linearity. However, on the
basis of our experience, using this particular internal standard
at higher concentrations will require some measures to be
taken to counter this effect.
Another problem we faced was the question of chromato-
graphic separation. All our analytes have similar pKa values
and similar overall hydrophobicity, meaning that several con-
ventional RPLC columns failed to provide sufficient separa-
tion, the biggest problem here being the overlap between 7-
alpha-methylthiospironolactone and canrenone. Various
Table 2 Accuracy data (n = 5 for
within-run accuracy; n = 3 for
between-run accuracy) in spiked
plasma samples
Analyte Accuracy (%)
At the LLOQ level Low, medium, and high
concentration QC-s
Within-run Between-run Within-run Between-run
Spironolactone −19.7…13.5 −19.7…13.5 −7.4…6.4 −7.4…5.5
7-Alpha-methylthiospironolactone −5.9…8.8 −5.9…1.5 1.1…11.4 2.1…11.4
Canrenone −10.9…18.2 −5.1…18.2 0.6…14.7 0.6…11.5
Quality control samples at low (4 ng/ml), medium (80 ng/ml), and high (220 ng/ml) concentration
Table 3 Precision data (n = 5 for
within-run precision; n = 3 for
between-run precision) in spiked
plasma samples
Analyte Precision (CV%)
At the LLOQ level Low, medium, and high
concentration QC-s
Within-run Between-run Within-run Between-run
Spironolactone 8.9 7.9 3.2 2.7
7-Alpha-methylthiospironolactone 4.0 2.1 2.7 2.1
Canrenone 7.8 7.5 2.7 2.1
Quality control samples at low (4 ng/ml), medium (80 ng/ml), and high (220 ng/ml) concentration
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common solvent mixtures used in LC-MS were tested, but
sufficient separation was not achieved until THF was added
to the mixture. The effect of THF in our case was the accel-
eration of the retention of spironolactone and 7-alpha-
methylthiospironolactone, resulting in a cleaner separation
from canrenone (Fig. 2). As to why the separationwas deemed
so crucial in MS/MS analysis—it appeared that two out of our
three analytes largely decomposed (in-source CID) in the ESI
source or ion transport and declustering region of MS preced-
ing the first quadrupole. Spironolactone lost its thioacetyl- and
7-alpha-methylthiospironolactone its thiomethyl group, ren-
dering them indistinguishable by m/z from canrenone with
molecular ions being hardly detectable. The best MS/MS tran-
sition (Table 1) for spironolactone and canrenone found (as
already reported by others [12, 13]) was m/z 341 [M+H]+
->m/z 107. Although 7-alpha-methylthiospironolactone was
quantified on different transition, it was still present in notice-
able amounts on this one.
The most problematic issue, however, was the ionization of
analytes. The difficulties ionizing steroid-like molecules have
been noted previously [14–16], and as a potential solution to
help them acquire a charge more easily, the eluent additive
ammonium fluoride has been proposed [14–16]. NH4F has
also been found to aid the ionization of various other mole-
cules [14–20], but with some exceptions [19] the increased
ionization efficiency has been reported for negative mode.
For our system, spironolactone and its two metabolites, we
observed a strong increase in ionization efficiency in the
Table 4 Stability results. Evaluated for QC samples (n = 5)



















Freeze-thaw (3 cycles) 92.5 (5.1) 86.0 (2.6) 94.0 (4.6) 92.6 (2.2) 91.8 (10.6) 98.9 (4.4)
Short term (24 h, 20 °C) 52.4 (6.3) 39.1 (2.2) 83.6 (3.3) 81.4 (4.2) 113.4 (5.0) 130.3 (7.6)
Long term (∼5 months, −70 °C)a 110.2 (2.1) 107.4 (0.8) 107.9 (2.9) 110.9 (1.5) 114.0 (5.8) 108.9 (0.6)
On-instrument (25 h, 4 °C)b 97.8 (1.9) 96.8 (2.7) 99.2 (3.4)
a Low and high have different values here: 0.60 and 224.70 ng/ml for spironolactone, 0.57 and 211.71 ng/ml for 7-alpha-methylthiospironolactone, and
0.59 and 220.53 ng/ml for canrenone
b Calculated over 16 calibration points (0.5…250)
Table 5 Matrix effects for spironolactone, 7-alpha-methylthiospironolactone, canrenone, and IS
Concentration Matrix MF (%) IS normalized MF (%)
Spironolactone 7-Alpha-
methylthiospironolactone
Canrenone IS Spironolactone 7-Alpha-
methylthiospironolactone
Canrenone
Low, 3 ng/ml Matrix 1 58.2% 74.2% 72.8% 56.9% 102.3% 130.4% 128.1%
Matrix 2 58.3% 75.7% 72.2% 57.9% 100.7% 130.7% 124.8%
Matrix 3 57.3% 73.9% 70.5% 58.2% 98.3% 126.8% 121.0%
Matrix 4 57.0% 69.9% 70.2% 57.9% 98.3% 120.7% 121.2%
Matrix 5 60.2% 67.6% 69.2% 61.0% 98.6% 110.9% 113.5%
Matrix 6 59.2% 71.6% 68.8% 59.8% 99.0% 119.6% 114.9%
CV% 2.1% 4.2% 2.3% 2.6% 1.6% 6.2% 4.7%
High, 200 ng/ml Matrix 1 64.8% 73.1% 79.5% 64.6% 100.4% 113.2% 123.1%
Matrix 2 66.7% 69.3% 77.6% 65.8% 101.3% 105.3% 117.9%
Matrix 3 67.4% 67.4% 77.1% 68.8% 98.0% 98.0% 112.1%
Matrix 4 66.1% 66.3% 72.7% 67.9% 97.3% 97.6% 106.9%
Matrix 5 66.7% 68.4% 72.9% 67.2% 99.2% 101.8% 108.6%
Matrix 6 67.1% 68.4% 77.1% 67.3% 99.7% 101.7% 114.5%
CV% 1.4% 3.4% 3.6% 2.3% 1.5% 5.6% 5.3%
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positive mode. Our experiments to find an optimal NH4F con-
centration revealed that with plasma sample injections, the
signal with ammonium fluoride was on average about 70
times higher than without it [24] (Fig. 3). To the best of our




The development of LC-MS/MS methods to determine poorly
ionizable compounds from limited volume samples (pre-clinical
studies or clinical trials on pediatric patients) is challenging. The
use of eluent additives such as NH4F can help boost ionization
and enhance the signal; in this case, the increase was about 70
times. The lowest limit of quantification of 0.5 ng/ml was
demonstrated using only 50 μl of blood plasma, making the
method suitable for use in pediatric patients’ samples.
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